
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Mission: Extend human healthspan by epigenetically reprogramming aged cells to restore youthful function
Platform: Discovery Engine combining high-throughput functional genomics, single-cell multi‑omics, pooled perturbation screening, and machine learning
Funding (disclosed): $170M across a $40M Series A (May 2023) and $130M Series B (May 2025)
Notable founders: Brian Armstrong, Blake Byers, Jacob C. Kimmel (also listed: Greg Johnson)
Early programs: Liver, immune, and vascular systems
Team size (reported): 34 (as of May 2025)
Age-related disease and loss of cellular function due to epigenetic aging
2022
Biotechnology Research
$40M
Investors included Dimension Capital, Founders Fund, Kleiner Perkins, with participation from angels such as Eric Schmidt, Elad Gil, Garry Tan, and Fred Ehrsam.
$130M
Series B included new investors (e.g., Nat Friedman & Daniel Gross, Khosla Ventures, Human Capital, Valor Equity Partners) alongside returning backers such as Dimension Capital and Founders Fund and multiple angel investors.
$45M
Described as additional financing including participation from Eli Lilly & Company, Duke Management Company, Section 32, and others.
“Backed by top-tier venture firms (Kleiner Perkins, Founders Fund, Dimension Capital, Khosla Ventures), strategic/corporate investors including Eli Lilly, university management company participation, and numerous prominent angel investors.”
| Company |
|---|
================ NewLimit is a biotechnology company working to radically extend human healthspan. We're developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale. =============== NewLimit is seeking an scientist with experience in liver biology and metabolism to join our Metabolism team. Our Metabolism team is developing reprogramming medicines to restore youthful function in aged hepatocytes in the context of metabolic disease. In this role, you will develop and perform assays for hepatocyte function, contribute to team decision making, and serve as a subject matter expert within NewLimit to enable our therapeutic development efforts. As a Scientist on our team, you will: * Collaborate with our Single Cell Technology, Epigenetic Editing, and Predictive Modeling teams to design, build, and test epigenetic reprogramming interventions for aged and diseased hepatocytes * Develop assays to measure hepatocyte function both and * Evaluate epigenetic reprogramming payloads using and functional assays to select therapeutic candidates * Develop methods for delivery of nucleic acid payloads to hepatocytes in collaboration with our Epigenetic Editing team * Analyze and interpret experimental data to drive pre-clinical decision making ================ * Ph.D. in cell biology, molecular biology, biochemistry or a related field or equivalent industry experience (5+ years) * Experience with primary liver cell isolation and functional characterization * Experience working with mouse models of liver dysfunction * Experience with transgenic manipulation of liver cells either (e.g. using viral vectors, nucleic acid delivery) ================ * History of contributing to a drug development program at the pre-clinical or clinical development stage * Experience leading the design and execution of pre-clinical studies in mouse models * Experience with single cell genomics methods * Experience with pooled screening approaches using bulk or single cell read-outs (e.g. CRISPR fitness screens, Perturb/CROP-seq) ============ NewLimit offers generous benefits to ensure our team can focus on our mission: * Health, dental, and vision insurance * 401(k) with company match * Paid parental leave * Industry-leading paid time off (PTO) — 20 days/year for all employees + holidays * Meals and snacks on-site